The Correlation Between Follicular Fluid Pregnancy-associated Plasma Protein A Levels, Fertilization, and Embryo Quality in GnRH Agonist and GnRH Antagonist Protocols in ART Cycles

Overview

Journal Iran J Reprod Med

Specialty Reproductive Medicine

Date 2014 Sep 24

PMID 25246915

Citations 2

Authors

Razieh Dehghani Firouzabadi

Farnaz Mohammadian

Mehri Mashayekhy

Robab Davar

Maryam Eftekhar

Affiliations

Soon will be listed here.

Abstract

Background: Determination of oocyte fertilization and embryo quality are one of the most important purposes in ART cycles. Follicular fluid provides an important microenvironment for development of oocytes and some biochemical characteristics of the follicular fluid, such as pregnancy-associated plasma protein-A (PAPP-A), may play an important role in prediction of success rate of ART.

Objective: This study was performed to evaluate whether there was any difference in follicular fluid PAPP-A, fertilization, and embryo quality between GnRH agonist long protocol and flexible GnRH antagonist multiple-dose protocol in ART cycles.

Materials And Methods: A total of 100 women who were candidates for ART were enrolled the study and were divided into two groups, GnRH agonist (GnRHa) long protocol (n=51) and flexible GnRH antagonist (GnRHant) multiple-dose protocol (n=49). Follicular fluid sample was obtained from a single mature follicle and follicular fluid PAPP-A level, fertilization and embryo quality of the same oocyte were evaluated in both groups.

Results: There was no significant difference in the mean levels of follicular fluid PAPP-A between the GnRHa protocol and GnRHant protocol (3.5±1.4 vs. 3.8±1.9, respectively). The mean levels of follicular fluid PAPP-A in fertilized oocyte and good quality embryo were comparable in GnRHa and GnRHant protocols.

Conclusion: Our data indicated that no differences of follicular fluid PAPP-A levels were observed between cycles using GnRHa long protocol and those of using flexible GnRHant multiple-dose protocol.

Citing Articles

Increased Uterine NK cell numbers and perforin expression during the implantation phase in IVF Cycles with GnRH Antagonist Protocol.

Xu B, Wang J, Xia L, Zhang D, Wu X, Zhang A Sci Rep. 2017; 7:39912.

PMID: 28045093 PMC: 5206673. DOI: 10.1038/srep39912.

Correlation between follicular fluid 25-OH vitamin D and assisted reproductive outcomes.

Farzadi L, Khayatzadeh Bidgoli H, Ghojazadeh M, Bahrami Z, Fattahi A, Latifi Z Iran J Reprod Med. 2015; 13(6):361-6.

PMID: 26330851 PMC: 4555056.

References

Choi Y, Ku S, Jee B, Suh C, Choi Y, Kim J . Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A concentrations and their ratios between GnRH agonist and GnRH antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer patients. Hum Reprod. 2006; 21(8):2015-21. DOI: 10.1093/humrep/del091. View

Rezabek K, Moosova M, Pavelkova J, Moos J, Filova V . [Follicular fluid and serum concentrations of PAPP-A in OHSS risk group of women undergoing IVF stimulation]. Ceska Gynekol. 2009; 74(2):80-4. View

Hugues J, Cedrin Durnerin I . Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update. 1998; 4(1):83-101. DOI: 10.1093/humupd/4.1.83. View

Wang T, Chang C, Wu H, Chiu Y, Chen C, Wang H . Insulin-like growth factor-II (IGF-II), IGF-binding protein-3 (IGFBP-3), and IGFBP-4 in follicular fluid are associated with oocyte maturation and embryo development. Fertil Steril. 2006; 86(5):1392-401. DOI: 10.1016/j.fertnstert.2006.03.064. View

Erickson G, Shimasaki S . The physiology of folliculogenesis: the role of novel growth factors. Fertil Steril. 2001; 76(5):943-9. DOI: 10.1016/s0015-0282(01)02859-x. View

Revelli A, Delle Piane L, Casano S, Molinari E, Massobrio M, Rinaudo P . Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics. Reprod Biol Endocrinol. 2009; 7:40. PMC: 2685803. DOI: 10.1186/1477-7827-7-40. View

Mason H, Holly J, Franks S . Potent inhibition of human ovarian steroidogenesis by insulin-like growth factor binding protein-4 (IGFBP-4). J Clin Endocrinol Metab. 1998; 83(1):284-7. DOI: 10.1210/jcem.83.1.4630. View

Rivera G, Chandrasekher Y, Evans A, Giudice L, Fortune J . A potential role for insulin-like growth factor binding protein-4 proteolysis in the establishment of ovarian follicular dominance in cattle. Biol Reprod. 2001; 65(1):102-11. DOI: 10.1095/biolreprod65.1.102. View

Choi D, Hwang S, Lee E, Park C, Yoon B, Lee J . Recombinant FSH and pregnancy-associated plasma protein. Eur J Obstet Gynecol Reprod Biol. 2003; 109(2):171-6. DOI: 10.1016/s0301-2115(02)00514-6. View

10.

TAYMOR M . The regulation of follicle growth: some clinical implications in reproductive endocrinology. Fertil Steril. 1996; 65(2):235-47. DOI: 10.1016/s0015-0282(16)58077-7. View

11.

Conover C, Faessen G, Ilg K, Chandrasekher Y, Christiansen M, Overgaard M . Pregnancy-associated plasma protein-a is the insulin-like growth factor binding protein-4 protease secreted by human ovarian granulosa cells and is a marker of dominant follicle selection and the corpus luteum. Endocrinology. 2001; 142(5):2155. DOI: 10.1210/endo.142.5.8286. View

12.

Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reissmann T . Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994; 9(5):788-91. DOI: 10.1093/oxfordjournals.humrep.a138597. View

13.

Brus L, Lambalk C, de Koning J, Helder M, Janssens R, Schoemaker J . Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum Reprod. 1997; 12(4):769-73. DOI: 10.1093/humrep/12.4.769. View

14.

Ludwig M, Katalinic A, Diedrich K . Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet. 2002; 265(4):175-82. DOI: 10.1007/s00404-001-0267-2. View

15.

Adashi E . Insulin-like growth factors as determinants of follicular fate. J Soc Gynecol Investig. 1995; 2(6):721-6. View

16.

Parinaud J, Beaur A, Bourreau E, Vieitez G, PONTONNIER G . Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells. Fertil Steril. 1988; 50(4):597-602. DOI: 10.1016/s0015-0282(16)60190-5. View

17.

Depa-Martynow M, Jedrzejczak P, Pawelczyk L . Pronuclear scoring as a predictor of embryo quality in in vitro fertilization program. Folia Histochem Cytobiol. 2008; 45 Suppl 1:S85-9. View

18.

Suh J, Lee E, Hwang S, Yoon S, Yoon B, Bae D . Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle. Eur J Obstet Gynecol Reprod Biol. 2003; 112(1):65-8. DOI: 10.1016/s0301-2115(03)00317-8. View

19.

Hourvitz A, Widger A, Filho F, Chang R, Adashi E, Erickson G . Pregnancy-associated plasma protein-A gene expression in human ovaries is restricted to healthy follicles and corpora lutea. J Clin Endocrinol Metab. 2001; 85(12):4916-20. DOI: 10.1210/jcem.85.12.7169. View

20.

Funston R, Seidel Jr G . Gonadotropin-releasing hormone increases cleavage rates of bovine oocytes fertilized in vitro. Biol Reprod. 1995; 53(3):541-5. DOI: 10.1095/biolreprod53.3.541. View